Takeda Pharmaceutical Co Ltd
TAK14.915USD
+0.085+0.57%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
47.12BMarket Cap
209.33P/E TTM
More Details of Takeda Pharmaceutical Co Ltd Company
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Takeda Pharmaceutical Co Ltd Info
Ticker SymbolTAK
Company nameTakeda Pharmaceutical Co Ltd
IPO dateJun 21, 2085
CEOWeber (Christophe)
Number of employees47455
Security typeDepository Receipt
Fiscal year-endJun 21
Address4F
CityCHUO-KU
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryJapan
Postal code103-8668
Phone81332782111
Websitehttps://www.takeda.com/
Ticker SymbolTAK
IPO dateJun 21, 2085
CEOWeber (Christophe)
Company Executives of Takeda Pharmaceutical Co Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Gastrointestinal diseases
339.30B
30.66%
Plasma derivatives
260.90B
23.57%
Rare diseases
196.40B
17.75%
Oncology
138.80B
12.54%
Neuroscience
108.60B
9.81%
Other
62.70B
5.67%
By RegionUSD
Name
Revenue
Proportion
United States
546.70B
49.40%
Europe And Canada (Country)
262.30B
23.70%
Japan
108.00B
9.76%
Latin America
57.60B
5.20%
China (Country)
43.20B
3.90%
Other
88.90B
8.03%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Gastrointestinal diseases
339.30B
30.66%
Plasma derivatives
260.90B
23.57%
Rare diseases
196.40B
17.75%
Oncology
138.80B
12.54%
Neuroscience
108.60B
9.81%
Other
62.70B
5.67%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
UBS Financial Services, Inc.
0.19%
Fidelity Management & Research Company LLC
0.13%
Brandes Investment Partners, L.P.
0.12%
Other
98.94%
Shareholders
Shareholders
Proportion
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
UBS Financial Services, Inc.
0.19%
Fidelity Management & Research Company LLC
0.13%
Brandes Investment Partners, L.P.
0.12%
Other
98.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
1.85%
Hedge Fund
0.32%
Investment Advisor/Hedge Fund
0.31%
Research Firm
0.21%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
Other
97.27%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
606
78.67M
2.49%
-1.76M
2025Q2
594
72.78M
2.30%
-6.62M
2025Q1
603
72.05M
2.31%
-7.59M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital Research Global Investors
13.30M
0.42%
+94.57K
+0.72%
Jun 30, 2025
Parametric Portfolio Associates LLC
5.97M
0.19%
+676.71K
+12.78%
Jun 30, 2025
UBS Financial Services, Inc.
3.98M
0.13%
+2.28M
+133.74%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.08M
0.13%
+275.19K
+7.23%
Jun 30, 2025
Brandes Investment Partners, L.P.
3.71M
0.12%
+208.14K
+5.94%
Jun 30, 2025
Renaissance Technologies LLC
3.30M
0.1%
+141.50K
+4.48%
Jun 30, 2025
Goldman Sachs Asset Management, L.P.
2.85M
0.09%
-44.41K
-1.53%
Jun 30, 2025
Aperio Group, LLC
3.20M
0.1%
+574.34K
+21.83%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
1.22M
0.04%
-181.77K
-12.98%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
VanEck Pharmaceutical ETF
5.05%
SGI Enhanced Global Income ETF
0.76%
Adasina Social Justice All Cap Global ETF
0.49%
First Trust Value Line Dividend Index Fund
0.38%
ActivePassive International Equity ETF
0.3%
Avantis Responsible International Equity ETF
0.09%
Avantis International Equity ETF
0.05%
Roundhill GLP-1 & Weight Loss ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Invesco Zacks Multi-Asset Income ETF
0%
View more
VanEck Pharmaceutical ETF
Proportion5.05%
SGI Enhanced Global Income ETF
Proportion0.76%
Adasina Social Justice All Cap Global ETF
Proportion0.49%
First Trust Value Line Dividend Index Fund
Proportion0.38%
ActivePassive International Equity ETF
Proportion0.3%
Avantis Responsible International Equity ETF
Proportion0.09%
Avantis International Equity ETF
Proportion0.05%
Roundhill GLP-1 & Weight Loss ETF
Proportion0%
DFA Dimensional International Core Equity 2 ETF
Proportion0%
Invesco Zacks Multi-Asset Income ETF
Proportion0%
Dividend
A total of
1.44T
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Sep 08, 2025
TAK.NB Final Cash Dividend of gross USD 0.322144 paid on Dec 11, 2025 going ex on Sep 30, 2025
Sep 30, 2025
Dec 11, 2025
Sep 30, 2025
Mar 04, 2025
TAK.NB Approximate interim Cash Dividend of gross USD 0.33901 paid on Jul 07, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Jul 07, 2025
Mar 31, 2025
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Takeda Pharmaceutical Co Ltd?
The top five shareholders of Takeda Pharmaceutical Co Ltd are:
Capital Research Global Investors holds 13.30M shares, accounting for 0.42% of the total shares.
Parametric Portfolio Associates LLC holds 5.97M shares, accounting for 0.19% of the total shares.
UBS Financial Services, Inc. holds 3.98M shares, accounting for 0.13% of the total shares.
Fidelity Management & Research Company LLC holds 4.08M shares, accounting for 0.13% of the total shares.
Brandes Investment Partners, L.P. holds 3.71M shares, accounting for 0.12% of the total shares.
Capital Research Global Investors holds 13.30M shares, accounting for 0.42% of the total shares.
Parametric Portfolio Associates LLC holds 5.97M shares, accounting for 0.19% of the total shares.
UBS Financial Services, Inc. holds 3.98M shares, accounting for 0.13% of the total shares.
Fidelity Management & Research Company LLC holds 4.08M shares, accounting for 0.13% of the total shares.
Brandes Investment Partners, L.P. holds 3.71M shares, accounting for 0.12% of the total shares.
What are the top three shareholder types of Takeda Pharmaceutical Co Ltd?
The top three shareholder types of Takeda Pharmaceutical Co Ltd are:
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.
How many institutions hold shares of Takeda Pharmaceutical Co Ltd (TAK)?
As of 2025Q3, 606 institutions hold shares of Takeda Pharmaceutical Co Ltd, with a combined market value of approximately 78.67M, accounting for 2.49% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.19%.
What is the biggest source of revenue for Takeda Pharmaceutical Co Ltd?
In FY2026Q1, the Gastrointestinal diseases business generated the highest revenue for Takeda Pharmaceutical Co Ltd, amounting to 339.30B and accounting for 30.66% of total revenue.
